KAIS Atlas
Every payer's lines on a disease, quoted at the source.
For a disease and a drug, KAIS Atlas reads what the payers in the library publish and quotes each line with its document, its position and its date. Where a payer prints nothing, the absence is named. Built for market access, medical affairs and the teams who plan a launch.
What the Atlas holds
Every payer on a disease, in its own words.
Research teams read the same quoted lines a practice would meet, before the first patient does.
Disease pages
One page per disease, with the payers whose published documents carry lines that name it, grouped by payer.
Quoted lines, at their source
Every line is the payer's own words, with the document, its edition, the line's position and the link. Nothing is paraphrased into a requirement.
The roll-up by payer, absences named
For each payer: what its documents print about the disease and the drug class, and where it prints nothing. An absence is shown as an absence, never filled in.
What access and contracting teams work from
The exact restriction language, the step order and the edition history for each payer, quoted and dated. It is the ground a team stands on before it negotiates.
Ask KAIS
Ask a question about the disease or the drug in plain words. The answer comes back with the lines it rests on.
A public sample
One medicine, three payers, each in its own words.
Wegovy (semaglutide) for commercial plans, as read on November 4, 2026. These pages are open to anyone. An Atlas Snapshot does this for a whole disease, across the payers in the library, with the absences named.
Aetna
Two published documents. The policy lists prior authorization and a quantity limit. One of its lines, word for word: “baseline body mass index (BMI) in the 95th percentile or greater standardized for age and sex (obesity)”.
Cigna
Two published documents: one for weight loss and one for metabolic dysfunction-associated steatohepatitis. The policy lists prior authorization.
UnitedHealthcare
One published document, for cardiovascular risk reduction and MASH only. One of its lines, word for word: “Documentation of positive clinical response to Wegovy injection”.
KAIS Atlas Forecast
Not a model. The payer's own lines, quoted, with the watch that grades us.
For a drug on its way to market, the Forecast reads what each payer prints today for the comparator and lays out what that payer will ask. When the payer publishes, the Forecast grades itself in front of you.
Criteria Forecast
What each payer will carry into criteria for a new drug, read from the lines it prints for the comparator today. Every element carries its source line.
Criteria Lineage
Who writes the criteria each plan publishes: the plan itself, or a pharmacy benefit manager's template it publishes under its own name. One edition change maps to every plan it reaches.
Setting Map
Where the drug is paid, Part A or Part B, inpatient or outpatient, read from each document's own text. A document governs a drug only where its printed setting meets the drug's.
Payment Layer
How the stay or the dose is paid: the DRG, the new technology add-on payment and state carve-outs, by payer and state.
Edition Watch
The dated change log on the drug's document set. When a payer publishes criteria that name the drug, the forecast is marked matched, changed or absent, with the date.
Licensing
Licensed per sponsor, per disease.
The Atlas starts with a Snapshot of your disease across the payers and runs live through the year with Edition Watch. The terms are set in writing before any work starts.
The Atlas is for your own market access and medical affairs teams to read and plan from. To put the same cited rules inside a product, a hub or an AI workflow, that is KAIS Hub Access.
Payers and pharmacy benefit managers appear by name as plain text. Apex Flow is not affiliated with, endorsed by, or sponsored by any company named. The Atlas holds published documents only and never takes a patient, a plan or a date of service.